RXi Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch RXII and buy or sell other stocks, ETFs, and their options commission-free!

About RXII

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. 

CEO
Angelos M. Stergiou, MD
CEOAngelos M. Stergiou, MD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2006
Founded2006
Employees
Employees

RXII Key Statistics

Market cap
2.11B
Market cap2.11B
Price-Earnings ratio
-49.56
Price-Earnings ratio-49.56
Dividend yield
Dividend yield
Average volume
6.84M
Average volume6.84M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$15.88
52 Week high$15.88
52 Week low
$1.39
52 Week low$1.39

Stock Snapshot

RXi Pharmaceuticals(RXII) stock is priced at $2.32, giving the company a market capitalization of 2.11B. It carries a P/E multiple of -49.56.

On 2026-07-26, RXi Pharmaceuticals(RXII) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for RXi Pharmaceuticals(RXII) stock has reached 0, versus its average volume of 6.84M.

The stock's 52-week range extends from a low of $1.39 to a high of $15.88.

The stock's 52-week range extends from a low of $1.39 to a high of $15.88.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.